verified SJR 1,752 · Q1 • database Scopus / SJR & Web of Science indexed

Ireland · Elsevier Ireland Ltd

workspace_premium Q1 — Oncology lock Subscription

Lung Cancer

Lung Cancer is a journal indexed in SJR in Oncology and Cancer Research with an H index of 154. It has an SJR impact factor of 1,752 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,752.

Lung Cancer focuses its scope in these topics and keywords: lung, cancer, cell, nonsmall, combination, egfr, patients, treatment, chemotherapy, advanced, ...

ISSN: 0169-5002

Publisher: Elsevier Ireland Ltd

Category: Oncology

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

1,752 Q1

H-index 154

Acceptance rate pie_chart

22% Selective

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

NPD Subscription

Non-OA path NPD

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

1,752

H-index

154

Docs (year)

229

Docs 3y

774

Total refs

8336

Cites 3y

3233

Citable 3y

700

Cites/Doc 2y

4.25

Ref/Doc

36.4

Immediate OA

—

Embargoed OA

NPD

Non OA / Submission

—

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Medical ethics and therapeutic progress: the example of lung cancer. Hippocrates to the rescue!

Why are bronchopulmonary carcinoid tumours unique?

Varese meeting report

Small cell lung cancer in women: risk associated with smoking, prior respiratory disease, and occupation

Serum levels of KL-6 are useful biomarkers for severe radiation pneumonitis

Reply to Grannis

Pulmonary veno-occlusive disease after neoadjuvant mitomycin chemotherapy and surgery for lung carcinoma

Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study

Organizing pneumonia adjacent to lung cancer

Occupational Lung Disease-An International Perspective, Edited by Daneile E. Banks and John E. Parker. Chapman and Hall, Lippincott-Raven Publishers 1998. ISBN 0 412 73630 6

Morbidity after induction therapy and surgery in non small cell lung cancer (NSCLC). Focus on pulmonary function

Metastasis to the penis in a patient with squamous cell carcinoma of the lung with a review of reported cases

SHOW MORE ARTICLES

Overexpression of Hrad17 gene in non-small cell lung cancers correlated with lymph node metastasis

Lung cancer risk and red meat consumption among Iowa women

Identification of lung cancer by autopsy: an indicator for clinical underdiagnosis

Hospital based survey of lung cancer in Turkey, a developing country, where smoking is highly prevalent

High-resolution computed tomography of bronchioloalveolar cell carcinoma

High prevalence of atypical adenomatous hyperplasia of the lung in autopsy specimens from elderly patients with malignant neoplasms

High cyclin E and low p27/Kip1 expressions are potentially poor prognostic factors in lung adenocarcinoma patients

GSTM1 genotypes in elderly tumour-free smokers and non-smokers

Gemcitabine plus vinorelbine in stage IIIB or IV non-small cell lung cancer (NSCLC): a multicentre phase II clinical trial

Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial

Evaluation of telomerase activity in bronchial lavage as a potential diagnostic marker for malignant lung disease

Etoposide (VP-16) and cisplatin at maximum tolerated dose in non-small cell lung carcinoma: a Cancer and Leukemia Group B study

FAQs

Lung Cancer has an SJR of 1,752 (best quartile Q1) in the CountryOfPapers database.

Immediate OA APC is not available (NPD).

The acceptance rate recorded for Lung Cancer is 22%.

Lung Cancer

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Lung Cancer?

What is the APC / publication cost?

What is the acceptance rate?